The safety, pharmacokinetics and pharmacodynamics of the cancer drug candidate E-602 invented by Nobel laureates in non-human primates

Sialic acid is a special glycan that can be recognized by a range of surface proteins that are found primarily on innate immune cells but also on activated T cells at

E-602 is a new, first-class engineered human sialidase (Neu2)Fc fusion developed for cancer treatment

Developed by Palleon, an innovative drug company founded by 2022 Nobel Laureate in Chemistry Carolyn Bertozzi, E-602 will provide data

To support clinical development, we conducted a good laboratory-practice, one-month repeated dosing toxicity study evaluating the pharmacokinetics (PK) parameters, pharmacodynamic (PD) effects, and safety profiles of E-602 in crab-eating monkeys by weekly intravenous infusion of E-602 for a total of five doses

Despite the short half-life of E-602, the PD effect of desialylation of immune cells persists on T cells for up to 7 days, consistent with the enzymatic mechanism of action of E-602

At present, palleon has reached a strategic cooperation with Henlius Fuhong to jointly develop two bifunctional antibodies, sialidase fusion proteins, for the treatment of a variety of cancers

Original Source:

Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13.